John Weyl Winkelman, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Restless Legs Syndrome | 77 | 2025 | 235 | 22.950 |
Why?
|
Sleep Initiation and Maintenance Disorders | 31 | 2024 | 1106 | 5.330 |
Why?
|
Dopamine Agonists | 23 | 2023 | 347 | 5.290 |
Why?
|
Nocturnal Myoclonus Syndrome | 11 | 2025 | 52 | 4.260 |
Why?
|
Polysomnography | 31 | 2022 | 1871 | 2.200 |
Why?
|
gamma-Aminobutyric Acid | 10 | 2020 | 1141 | 2.120 |
Why?
|
Tetrahydronaphthalenes | 7 | 2019 | 85 | 1.930 |
Why?
|
Sleep | 25 | 2024 | 4818 | 1.930 |
Why?
|
Thiophenes | 7 | 2019 | 570 | 1.530 |
Why?
|
Disorders of Excessive Somnolence | 3 | 2020 | 279 | 1.150 |
Why?
|
Depressive Disorder, Major | 8 | 2023 | 4818 | 0.980 |
Why?
|
Actigraphy | 4 | 2024 | 527 | 0.970 |
Why?
|
Analgesics, Opioid | 13 | 2024 | 3837 | 0.940 |
Why?
|
Maltose | 1 | 2024 | 39 | 0.930 |
Why?
|
Sleep Medicine Specialty | 1 | 2025 | 72 | 0.910 |
Why?
|
Sleep, REM | 4 | 2022 | 595 | 0.900 |
Why?
|
Narcolepsy | 3 | 2022 | 200 | 0.900 |
Why?
|
Carbamates | 2 | 2018 | 192 | 0.870 |
Why?
|
Azepines | 2 | 2024 | 329 | 0.850 |
Why?
|
Benzothiazoles | 5 | 2022 | 248 | 0.840 |
Why?
|
Sleep Stages | 6 | 2022 | 706 | 0.810 |
Why?
|
Ferric Compounds | 1 | 2024 | 376 | 0.810 |
Why?
|
Copyright | 1 | 2021 | 13 | 0.790 |
Why?
|
Cross-Over Studies | 4 | 2024 | 2107 | 0.780 |
Why?
|
Sleep Apnea, Obstructive | 8 | 2020 | 1899 | 0.760 |
Why?
|
Dopamine Agents | 4 | 2018 | 188 | 0.730 |
Why?
|
Parasomnias | 1 | 2020 | 27 | 0.700 |
Why?
|
Movement | 6 | 2019 | 1490 | 0.700 |
Why?
|
Adrenoleukodystrophy | 1 | 2022 | 144 | 0.670 |
Why?
|
Triazoles | 2 | 2024 | 904 | 0.670 |
Why?
|
Brain Chemistry | 2 | 2014 | 958 | 0.660 |
Why?
|
Practice Guidelines as Topic | 8 | 2022 | 7454 | 0.620 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2013 | 3782 | 0.610 |
Why?
|
Mental Disorders | 5 | 2021 | 6873 | 0.590 |
Why?
|
Sleep-Wake Transition Disorders | 1 | 2017 | 2 | 0.580 |
Why?
|
Antidepressive Agents | 3 | 2018 | 2913 | 0.580 |
Why?
|
Fructose | 3 | 2020 | 284 | 0.570 |
Why?
|
Hypnotics and Sedatives | 5 | 2017 | 1191 | 0.570 |
Why?
|
Humans | 135 | 2025 | 768171 | 0.550 |
Why?
|
Double-Blind Method | 14 | 2024 | 12466 | 0.540 |
Why?
|
Bupropion | 1 | 2018 | 303 | 0.540 |
Why?
|
MAP Kinase Kinase 5 | 1 | 2015 | 10 | 0.510 |
Why?
|
Self Report | 4 | 2024 | 3773 | 0.510 |
Why?
|
Drug Synergism | 2 | 2016 | 1760 | 0.490 |
Why?
|
Dyssomnias | 2 | 2006 | 28 | 0.490 |
Why?
|
Glutamic Acid | 3 | 2020 | 1191 | 0.470 |
Why?
|
Ferritins | 3 | 2013 | 601 | 0.460 |
Why?
|
Cardiovascular Diseases | 9 | 2021 | 15662 | 0.450 |
Why?
|
Adult | 58 | 2025 | 223646 | 0.440 |
Why?
|
Gyrus Cinguli | 3 | 2020 | 1135 | 0.430 |
Why?
|
Neurodegenerative Diseases | 1 | 2022 | 1094 | 0.410 |
Why?
|
Middle Aged | 53 | 2024 | 223487 | 0.380 |
Why?
|
Anti-Obesity Agents | 2 | 2006 | 240 | 0.370 |
Why?
|
Male | 62 | 2024 | 364731 | 0.370 |
Why?
|
Leg | 4 | 2016 | 1088 | 0.370 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2013 | 372 | 0.370 |
Why?
|
Electroencephalography | 4 | 2020 | 6314 | 0.360 |
Why?
|
Female | 65 | 2024 | 397187 | 0.360 |
Why?
|
Opioid-Related Disorders | 3 | 2021 | 2188 | 0.350 |
Why?
|
Kidney Failure, Chronic | 4 | 2016 | 2496 | 0.350 |
Why?
|
Thalamus | 2 | 2014 | 1047 | 0.340 |
Why?
|
Occipital Lobe | 1 | 2012 | 376 | 0.340 |
Why?
|
Glutamine | 1 | 2013 | 577 | 0.340 |
Why?
|
Severity of Illness Index | 12 | 2023 | 15949 | 0.330 |
Why?
|
Aged | 40 | 2024 | 171502 | 0.330 |
Why?
|
Drug Tolerance | 2 | 2017 | 365 | 0.320 |
Why?
|
Neurology | 1 | 2017 | 786 | 0.320 |
Why?
|
Heart Rate | 5 | 2022 | 4214 | 0.310 |
Why?
|
Circadian Rhythm | 3 | 2024 | 2593 | 0.300 |
Why?
|
Administration, Oral | 1 | 2016 | 4034 | 0.300 |
Why?
|
Quality of Life | 8 | 2022 | 13490 | 0.300 |
Why?
|
Renal Dialysis | 3 | 2016 | 1791 | 0.300 |
Why?
|
Protons | 2 | 2012 | 1113 | 0.280 |
Why?
|
REM Sleep Behavior Disorder | 1 | 2008 | 111 | 0.280 |
Why?
|
Snoring | 2 | 2020 | 211 | 0.280 |
Why?
|
Iron | 5 | 2022 | 1813 | 0.270 |
Why?
|
Comorbidity | 8 | 2020 | 10590 | 0.260 |
Why?
|
Anticonvulsants | 2 | 2014 | 1923 | 0.260 |
Why?
|
Depressive Disorder | 2 | 2018 | 3721 | 0.260 |
Why?
|
Homeodomain Proteins | 1 | 2015 | 2430 | 0.260 |
Why?
|
Treatment Outcome | 17 | 2024 | 65379 | 0.250 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2008 | 197 | 0.250 |
Why?
|
Mental Health | 1 | 2020 | 3275 | 0.240 |
Why?
|
Prevalence | 10 | 2022 | 15869 | 0.240 |
Why?
|
Depression | 8 | 2023 | 8230 | 0.240 |
Why?
|
Brain | 8 | 2023 | 27362 | 0.230 |
Why?
|
Muscle Tonus | 1 | 2004 | 82 | 0.230 |
Why?
|
Up-Regulation | 1 | 2013 | 4149 | 0.220 |
Why?
|
Cell Membrane | 1 | 2013 | 3655 | 0.220 |
Why?
|
Neoplasm Proteins | 1 | 2015 | 3604 | 0.210 |
Why?
|
Arousal | 3 | 2019 | 1180 | 0.210 |
Why?
|
Registries | 4 | 2023 | 8375 | 0.200 |
Why?
|
Sodium Oxybate | 1 | 2022 | 36 | 0.200 |
Why?
|
Energy Metabolism | 1 | 2013 | 2907 | 0.190 |
Why?
|
Transdermal Patch | 3 | 2016 | 51 | 0.190 |
Why?
|
Trazodone | 2 | 2015 | 67 | 0.190 |
Why?
|
Pituitary-Adrenal System | 1 | 2004 | 555 | 0.180 |
Why?
|
Hypertension | 4 | 2017 | 8616 | 0.180 |
Why?
|
Electromyography | 3 | 2013 | 1401 | 0.180 |
Why?
|
Psychiatry | 2 | 2020 | 1716 | 0.180 |
Why?
|
Cross-Sectional Studies | 10 | 2021 | 26379 | 0.170 |
Why?
|
Cyclohexanecarboxylic Acids | 2 | 2013 | 139 | 0.170 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2004 | 702 | 0.170 |
Why?
|
Indoles | 3 | 2016 | 1836 | 0.170 |
Why?
|
Receptor, Galanin, Type 1 | 1 | 2019 | 1 | 0.170 |
Why?
|
Telemedicine | 1 | 2017 | 3109 | 0.160 |
Why?
|
Amines | 2 | 2013 | 280 | 0.160 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 13013 | 0.160 |
Why?
|
Myocardial Infarction | 2 | 2017 | 11519 | 0.160 |
Why?
|
Health Surveys | 4 | 2019 | 4057 | 0.160 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2022 | 16044 | 0.160 |
Why?
|
Behavior Therapy | 1 | 2005 | 886 | 0.160 |
Why?
|
Academies and Institutes | 2 | 2021 | 326 | 0.160 |
Why?
|
Schizophrenic Psychology | 1 | 2005 | 1649 | 0.150 |
Why?
|
Young Adult | 13 | 2022 | 60066 | 0.150 |
Why?
|
Life Style | 4 | 2019 | 3932 | 0.150 |
Why?
|
Nutrition Surveys | 2 | 2017 | 1738 | 0.150 |
Why?
|
Patient Care Management | 1 | 2021 | 303 | 0.150 |
Why?
|
Receptors, Opioid, mu | 1 | 2019 | 171 | 0.150 |
Why?
|
Advisory Committees | 2 | 2022 | 796 | 0.140 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2018 | 10763 | 0.140 |
Why?
|
Hippocampus | 1 | 2010 | 3783 | 0.140 |
Why?
|
GABA-A Receptor Agonists | 1 | 2017 | 86 | 0.140 |
Why?
|
Consensus | 5 | 2020 | 3211 | 0.140 |
Why?
|
Risk Factors | 15 | 2020 | 74944 | 0.140 |
Why?
|
Bipolar Disorder | 2 | 2017 | 5130 | 0.130 |
Why?
|
Statistics as Topic | 3 | 2009 | 2357 | 0.130 |
Why?
|
Methadone | 1 | 2019 | 317 | 0.130 |
Why?
|
Thiazoles | 1 | 2004 | 1542 | 0.130 |
Why?
|
Blood Cell Count | 1 | 2017 | 406 | 0.130 |
Why?
|
Pilot Projects | 2 | 2022 | 8741 | 0.130 |
Why?
|
Receptors, GABA-A | 1 | 2020 | 625 | 0.130 |
Why?
|
Transcription Factors | 1 | 2015 | 12171 | 0.130 |
Why?
|
Homocysteine | 1 | 2019 | 637 | 0.130 |
Why?
|
Case-Control Studies | 8 | 2020 | 22290 | 0.130 |
Why?
|
Longitudinal Studies | 2 | 2023 | 14783 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2021 | 789 | 0.120 |
Why?
|
Trans Fatty Acids | 1 | 2016 | 155 | 0.120 |
Why?
|
Morphine | 1 | 2019 | 658 | 0.120 |
Why?
|
Chronic Disease | 4 | 2021 | 9384 | 0.120 |
Why?
|
Anorexia Nervosa | 1 | 2024 | 1364 | 0.120 |
Why?
|
United States | 12 | 2025 | 73039 | 0.120 |
Why?
|
Energy Intake | 2 | 2016 | 2146 | 0.120 |
Why?
|
Alcohol-Related Disorders | 1 | 2016 | 243 | 0.110 |
Why?
|
Aged, 80 and over | 10 | 2019 | 59626 | 0.110 |
Why?
|
Research Report | 1 | 2017 | 369 | 0.110 |
Why?
|
Evidence-Based Medicine | 3 | 2016 | 3706 | 0.110 |
Why?
|
Protein Multimerization | 1 | 2019 | 966 | 0.110 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 500 | 0.110 |
Why?
|
Age of Onset | 1 | 2020 | 3346 | 0.110 |
Why?
|
Phosphorus Isotopes | 1 | 2013 | 125 | 0.110 |
Why?
|
Clonazepam | 2 | 2017 | 135 | 0.110 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2010 | 9016 | 0.110 |
Why?
|
Self-Injurious Behavior | 1 | 2019 | 568 | 0.100 |
Why?
|
Heart Failure | 1 | 2017 | 11879 | 0.100 |
Why?
|
Sodium, Dietary | 1 | 2016 | 426 | 0.100 |
Why?
|
Medical Records | 1 | 2018 | 1410 | 0.100 |
Why?
|
Phosphocreatine | 1 | 2013 | 261 | 0.100 |
Why?
|
Adolescent | 9 | 2018 | 89169 | 0.100 |
Why?
|
Time Factors | 5 | 2022 | 40220 | 0.100 |
Why?
|
Suicidal Ideation | 3 | 2022 | 1462 | 0.100 |
Why?
|
Transferrin | 1 | 2013 | 283 | 0.100 |
Why?
|
Opiate Substitution Treatment | 1 | 2016 | 452 | 0.100 |
Why?
|
Health Occupations | 1 | 2013 | 225 | 0.100 |
Why?
|
Aspartic Acid | 1 | 2014 | 577 | 0.100 |
Why?
|
Arthritis | 1 | 2017 | 684 | 0.100 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 1988 | 0.100 |
Why?
|
Respiration | 2 | 2016 | 1665 | 0.100 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2016 | 628 | 0.100 |
Why?
|
Perception | 1 | 2018 | 1209 | 0.090 |
Why?
|
Prescriptions | 1 | 2014 | 388 | 0.090 |
Why?
|
Curriculum | 1 | 2005 | 3782 | 0.090 |
Why?
|
Antiparkinson Agents | 1 | 2012 | 184 | 0.090 |
Why?
|
Clinical Trials as Topic | 3 | 2024 | 8052 | 0.090 |
Why?
|
Retrospective Studies | 7 | 2022 | 81760 | 0.090 |
Why?
|
Autonomic Nervous System | 1 | 2016 | 707 | 0.090 |
Why?
|
Electrocardiography | 2 | 2022 | 6412 | 0.090 |
Why?
|
Tachycardia, Ventricular | 1 | 2019 | 1309 | 0.090 |
Why?
|
Antipsychotic Agents | 1 | 2024 | 3081 | 0.090 |
Why?
|
Rodentia | 2 | 2022 | 262 | 0.090 |
Why?
|
Risk Assessment | 5 | 2021 | 24318 | 0.090 |
Why?
|
Calcium Channel Blockers | 1 | 2013 | 687 | 0.080 |
Why?
|
Age Factors | 4 | 2019 | 18415 | 0.080 |
Why?
|
Creatine | 1 | 2012 | 427 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2017 | 12543 | 0.080 |
Why?
|
Sleep Deprivation | 2 | 2008 | 848 | 0.080 |
Why?
|
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2008 | 70 | 0.080 |
Why?
|
History, 21st Century | 2 | 2014 | 1573 | 0.080 |
Why?
|
Cardiovascular System | 1 | 2016 | 841 | 0.080 |
Why?
|
Gene Frequency | 1 | 2015 | 3623 | 0.080 |
Why?
|
Suicide | 1 | 2019 | 1606 | 0.070 |
Why?
|
Radionuclide Imaging | 1 | 2012 | 2000 | 0.070 |
Why?
|
Sleep Apnea Syndromes | 1 | 2016 | 984 | 0.070 |
Why?
|
Iron Metabolism Disorders | 1 | 2007 | 24 | 0.070 |
Why?
|
Venous Thromboembolism | 1 | 2020 | 1882 | 0.070 |
Why?
|
Schizophrenia | 1 | 2005 | 6983 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 10397 | 0.070 |
Why?
|
Cerebellum | 1 | 2014 | 1522 | 0.070 |
Why?
|
Pain | 2 | 2021 | 5099 | 0.070 |
Why?
|
Levodopa | 1 | 2007 | 221 | 0.070 |
Why?
|
Patient Compliance | 1 | 2017 | 2697 | 0.070 |
Why?
|
Adenosine Triphosphate | 1 | 2013 | 2004 | 0.070 |
Why?
|
Wisconsin | 1 | 2006 | 122 | 0.070 |
Why?
|
Analgesics | 1 | 2013 | 1071 | 0.070 |
Why?
|
Cohort Studies | 5 | 2015 | 41753 | 0.070 |
Why?
|
Follow-Up Studies | 9 | 2019 | 39354 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 36741 | 0.070 |
Why?
|
Trace Elements | 1 | 2007 | 193 | 0.060 |
Why?
|
Symporters | 1 | 2008 | 363 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14729 | 0.060 |
Why?
|
Pneumonia | 1 | 2017 | 2163 | 0.060 |
Why?
|
Dreams | 1 | 2006 | 146 | 0.060 |
Why?
|
Evaluation Studies as Topic | 1 | 2008 | 1627 | 0.060 |
Why?
|
Extremities | 1 | 2010 | 870 | 0.060 |
Why?
|
Disease Progression | 1 | 2022 | 13668 | 0.060 |
Why?
|
Organ Size | 1 | 2010 | 2267 | 0.060 |
Why?
|
Histamine H1 Antagonists | 1 | 2005 | 101 | 0.060 |
Why?
|
Apnea | 1 | 2006 | 195 | 0.060 |
Why?
|
Patient Satisfaction | 1 | 2017 | 3490 | 0.060 |
Why?
|
Internship and Residency | 1 | 2005 | 5953 | 0.060 |
Why?
|
Societies, Medical | 1 | 2016 | 3968 | 0.060 |
Why?
|
Overweight | 1 | 2015 | 2448 | 0.060 |
Why?
|
Alleles | 1 | 2015 | 6894 | 0.060 |
Why?
|
Feeding Behavior | 1 | 2016 | 3205 | 0.060 |
Why?
|
Nonprescription Drugs | 1 | 2005 | 119 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4262 | 0.050 |
Why?
|
Blood Pressure | 2 | 2016 | 8543 | 0.050 |
Why?
|
Motor Neurons | 1 | 2008 | 870 | 0.050 |
Why?
|
Reference Values | 1 | 2010 | 4939 | 0.050 |
Why?
|
History, 20th Century | 1 | 2011 | 2766 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2015 | 4413 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 18065 | 0.050 |
Why?
|
Prospective Studies | 8 | 2017 | 54924 | 0.050 |
Why?
|
Odds Ratio | 2 | 2020 | 9669 | 0.050 |
Why?
|
Incidence | 5 | 2016 | 21538 | 0.050 |
Why?
|
Biological Availability | 1 | 2022 | 391 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8747 | 0.050 |
Why?
|
Homeostasis | 2 | 2014 | 3348 | 0.050 |
Why?
|
Body Mass Index | 4 | 2016 | 13053 | 0.050 |
Why?
|
Benzimidazoles | 1 | 2007 | 864 | 0.050 |
Why?
|
Psychomotor Agitation | 1 | 2024 | 307 | 0.050 |
Why?
|
Taste Disorders | 1 | 2021 | 37 | 0.050 |
Why?
|
Demography | 1 | 2006 | 1641 | 0.050 |
Why?
|
Genetic Markers | 1 | 2007 | 2603 | 0.050 |
Why?
|
Child | 3 | 2025 | 80917 | 0.040 |
Why?
|
Anisotropy | 1 | 2023 | 1292 | 0.040 |
Why?
|
Superoxide Dismutase | 1 | 2022 | 596 | 0.040 |
Why?
|
Benzodiazepines | 1 | 2005 | 1138 | 0.040 |
Why?
|
Coronary Disease | 1 | 2012 | 5919 | 0.040 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 5176 | 0.030 |
Why?
|
Brain Mapping | 1 | 2012 | 6684 | 0.030 |
Why?
|
Mendelian Randomization Analysis | 1 | 2022 | 1040 | 0.030 |
Why?
|
Taiwan | 1 | 2017 | 524 | 0.030 |
Why?
|
Valsalva Maneuver | 1 | 2016 | 99 | 0.030 |
Why?
|
Animals | 5 | 2022 | 169285 | 0.030 |
Why?
|
Brain Waves | 1 | 2020 | 417 | 0.030 |
Why?
|
Forecasting | 1 | 2005 | 2945 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2005 | 6029 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2016 | 367 | 0.030 |
Why?
|
Photoperiod | 1 | 2016 | 141 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2021 | 937 | 0.030 |
Why?
|
Cost of Illness | 1 | 2005 | 1951 | 0.030 |
Why?
|
Baroreflex | 1 | 2016 | 154 | 0.030 |
Why?
|
Anti-Anxiety Agents | 1 | 2017 | 405 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3436 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 843 | 0.030 |
Why?
|
Stroke | 1 | 2016 | 9755 | 0.030 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12795 | 0.030 |
Why?
|
Health Status | 1 | 2006 | 4091 | 0.030 |
Why?
|
Logistic Models | 1 | 2008 | 13290 | 0.030 |
Why?
|
Immobilization | 1 | 2013 | 229 | 0.030 |
Why?
|
Diffusion Tensor Imaging | 1 | 2023 | 2420 | 0.030 |
Why?
|
Diet Surveys | 1 | 2016 | 1160 | 0.020 |
Why?
|
Blood Pressure Determination | 1 | 2016 | 646 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2016 | 1375 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2016 | 12252 | 0.020 |
Why?
|
Cognition Disorders | 1 | 2005 | 3980 | 0.020 |
Why?
|
Weight Loss | 1 | 2003 | 2721 | 0.020 |
Why?
|
Caffeine | 1 | 2016 | 703 | 0.020 |
Why?
|
Anxiety | 1 | 2006 | 4672 | 0.020 |
Why?
|
Rest | 1 | 2016 | 948 | 0.020 |
Why?
|
Vegetables | 1 | 2016 | 1199 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2022 | 20225 | 0.020 |
Why?
|
Psychological Tests | 1 | 2012 | 643 | 0.020 |
Why?
|
Phenotype | 1 | 2007 | 16726 | 0.020 |
Why?
|
Exercise | 2 | 2016 | 5954 | 0.020 |
Why?
|
Fatigue | 1 | 2016 | 1557 | 0.020 |
Why?
|
Buprenorphine | 1 | 2016 | 667 | 0.020 |
Why?
|
Research Design | 1 | 2024 | 6209 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2005 | 4423 | 0.020 |
Why?
|
Diet | 2 | 2016 | 8089 | 0.020 |
Why?
|
Nurses | 1 | 2017 | 2501 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2019 | 8142 | 0.020 |
Why?
|
Internationality | 1 | 2013 | 1008 | 0.020 |
Why?
|
Mental Healing | 1 | 2007 | 28 | 0.020 |
Why?
|
Disease Management | 1 | 2017 | 2535 | 0.020 |
Why?
|
Wakefulness | 1 | 2013 | 1284 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2013 | 1489 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7601 | 0.020 |
Why?
|
Age Distribution | 1 | 2011 | 2873 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9613 | 0.020 |
Why?
|
Cause of Death | 1 | 2016 | 3721 | 0.020 |
Why?
|
Cell Line | 1 | 2019 | 15602 | 0.010 |
Why?
|
Aging | 1 | 2004 | 8743 | 0.010 |
Why?
|
Databases, Factual | 1 | 2019 | 8080 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4045 | 0.010 |
Why?
|
Rats | 1 | 2019 | 23782 | 0.010 |
Why?
|
Brain Ischemia | 1 | 2016 | 3007 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5884 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6525 | 0.010 |
Why?
|
Primary Health Care | 1 | 2017 | 4746 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14164 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 3252 | 0.010 |
Why?
|
Smoking | 1 | 2016 | 9092 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12077 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2007 | 4861 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2013 | 4978 | 0.010 |
Why?
|
Medicare | 1 | 2016 | 6809 | 0.010 |
Why?
|
Hospitalization | 1 | 2017 | 10840 | 0.010 |
Why?
|
Heart Diseases | 1 | 2007 | 2819 | 0.010 |
Why?
|
Mice | 1 | 2020 | 82049 | 0.010 |
Why?
|
Prognosis | 1 | 2011 | 30009 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2004 | 3929 | 0.010 |
Why?
|